Conference Coverage

The Latest

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

By Barbara Jungwirth

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

By Polly Clayden for HIV i-Base

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

By Mark Mascolini

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.

By Sony Salzman

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study

Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.

By Simon Collins for HIV i-Base

Bictegravir in the Body -- Preliminary Information About Drug Interactions

The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

By Myles Helfand

Taking Darunavir/Cobicistat With Novel Attachment Inhibitor BMS-663068 Is Safe

Taking darunavir/cobicistat (Prezcobix) with a new HIV drug known as BMS-663068, which is currently being studied, was safe and did not cause any serious reactions in two studies.

By Mark Mascolini

What's Hot in HIV Clinical Science

What are the hottest developments in HIV clinical science over the past year? Physician-researcher Adaora Adimora, M.D., M.P.H., brought us a brief tour of key highlights at the start of the IDWeek 2015 medical conference in San Diego.

By Sony Salzman

Unintended Pregnancies With Levonorgestrel Implant Due to Drug Interactions With Efavirenz-Based Antiretroviral Therapy

Three unintended pregnancies in women with levonorgestrel sub-dermal implants, receiving efavirenz-based antiretroviral therapy in a pharmacokinetic study, were reported in a late breaker presentation at CROI 2015.

By Polly Clayden for HIV i-Base